Key Takeaways from Eli Lilly and Company Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 – Exclusive Insights Revealed by Executive Patrik Jonsson About Groundbreaking Diabetes and Obesity Innovations

Indianapolis, IN – Eli Lilly and Company participated in the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024. Patrik Jonsson, the Executive Vice President and President of Lilly Diabetes and Obesity, along with other conference call participants, discussed the company’s current initiatives and future plans during the session.

Patrik Jonsson shared insights into his extensive experience at Eli Lilly and Company, spanning over three decades and various leadership roles across different regions. He discussed the company’s focus on introducing innovative medicines for Type 2 diabetes and chronic weight management, highlighting ongoing developments in their pipeline, including promising Phase 3 candidates.

The conversation delved into the challenges of meeting the increasing demand for obesity treatments, with Jonsson emphasizing the company’s investments in expanding manufacturing capacity to address the unmet medical needs in the market. He also provided updates on the progress of their new facilities and ongoing initiatives to enhance supply chain efficiency.

Jonsson’s discussion on Lilly’s commercialization strategies, pricing dynamics, and access to anti-obesity medications shed light on the company’s efforts to improve patient outcomes and expand market reach. He addressed key issues such as patient affordability, employer opt-ins, and reimbursement policies, underscoring the importance of multi-stakeholder collaborations in ensuring widespread access to innovative therapies.

The conversation also touched upon Lilly’s pipeline of novel treatments, including oral formulations like orforglipron, and the potential impact of these medications on addressing chronic conditions like obesity and diabetes. The discussion showcased Lilly’s commitment to advancing healthcare solutions that not only improve patient outcomes but also contribute to overall health and well-being.

As the conversation turned towards future prospects and emerging trends in the healthcare industry, Jonsson highlighted Lilly’s focus on patient-centric approaches, collaborations with regulatory bodies, and ongoing research efforts to address unmet medical needs. The session concluded with a positive outlook on Lilly’s growth trajectory and its dedication to advancing innovative solutions for global health challenges.